JP2013525455A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013525455A5 JP2013525455A5 JP2013508267A JP2013508267A JP2013525455A5 JP 2013525455 A5 JP2013525455 A5 JP 2013525455A5 JP 2013508267 A JP2013508267 A JP 2013508267A JP 2013508267 A JP2013508267 A JP 2013508267A JP 2013525455 A5 JP2013525455 A5 JP 2013525455A5
- Authority
- JP
- Japan
- Prior art keywords
- measured
- cancer
- compound
- powder
- diffraction pattern
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 11
- 238000000634 powder X-ray diffraction Methods 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 239000002245 particle Substances 0.000 claims 6
- 239000003381 stabilizer Substances 0.000 claims 6
- 238000001144 powder X-ray diffraction data Methods 0.000 claims 5
- 229910019142 PO4 Inorganic materials 0.000 claims 3
- 239000012736 aqueous medium Substances 0.000 claims 3
- 229920003086 cellulose ether Polymers 0.000 claims 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 3
- 239000010452 phosphate Substances 0.000 claims 3
- 229920000642 polymer Polymers 0.000 claims 3
- 239000000843 powder Substances 0.000 claims 3
- 238000004088 simulation Methods 0.000 claims 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 2
- 229920000609 methyl cellulose Polymers 0.000 claims 2
- 239000001923 methylcellulose Substances 0.000 claims 2
- 235000010981 methylcellulose Nutrition 0.000 claims 2
- 150000004682 monohydrates Chemical class 0.000 claims 2
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 229920001400 block copolymer Polymers 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 claims 1
- 229940043264 dodecyl sulfate Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 235000003599 food sweetener Nutrition 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- -1 sorbitan ester Chemical class 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 239000003765 sweetening agent Substances 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32971010P | 2010-04-30 | 2010-04-30 | |
| US61/329,710 | 2010-04-30 | ||
| PCT/US2011/034417 WO2011137274A1 (en) | 2010-04-30 | 2011-04-29 | Pharmaceutical compositions comprising n-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-l-(4-fluorophenyl)-2-oxo- 1,2-dihydropyridine-3 -carboxamide |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013525455A JP2013525455A (ja) | 2013-06-20 |
| JP2013525455A5 true JP2013525455A5 (enExample) | 2014-06-05 |
| JP5820874B2 JP5820874B2 (ja) | 2015-11-24 |
Family
ID=44209564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013508267A Active JP5820874B2 (ja) | 2010-04-30 | 2011-04-29 | Ｎ−（４−（２−アミノ−３−クロロピリジン−４−イルオキシ）−３−フルオロフェニル）−４−エトキシ−１−（４−フルオロフェニル）−２−オキソ−１，２−ジヒドロピリジン−３−カルボキサミドを含有する医薬組成物 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8911785B2 (enExample) |
| EP (1) | EP2563763B1 (enExample) |
| JP (1) | JP5820874B2 (enExample) |
| KR (1) | KR101897302B1 (enExample) |
| CN (1) | CN102971296B (enExample) |
| DK (1) | DK2563763T3 (enExample) |
| ES (1) | ES2533075T3 (enExample) |
| HR (1) | HRP20150105T1 (enExample) |
| MY (1) | MY183769A (enExample) |
| PH (1) | PH12012502019A1 (enExample) |
| PL (1) | PL2563763T3 (enExample) |
| PT (1) | PT2563763E (enExample) |
| RS (1) | RS53790B1 (enExample) |
| SG (1) | SG184891A1 (enExample) |
| SI (1) | SI2563763T1 (enExample) |
| SM (1) | SMT201500069B (enExample) |
| WO (1) | WO2011137274A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6216327B2 (ja) * | 2011-12-22 | 2017-10-18 | ライフ テクノロジーズ コーポレーション | 細胞培地および方法 |
| WO2016126012A1 (en) * | 2015-02-05 | 2016-08-11 | Boryung Pharmaceutical Co., Ltd | Tablet and method of preparing the same |
| KR101545268B1 (ko) | 2015-02-05 | 2015-08-20 | 보령제약 주식회사 | 정제 및 이의 제조방법 |
| WO2020150307A1 (en) * | 2019-01-15 | 2020-07-23 | The Translational Genomics Research Institute | Phosphonate conjugates and uses thereof |
| US20230257364A1 (en) * | 2022-02-16 | 2023-08-17 | Cmg Pharmaceutical Co., Ltd. | Pyridazinone-based compounds as axl, c-met, and mer inhibitors and methods of use thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6214344B1 (en) | 1995-06-02 | 2001-04-10 | Genetech, Inc. | Hepatocyte growth factor receptor antagonists and uses thereof |
| TR199900651T2 (xx) * | 1996-09-24 | 1999-07-21 | Eli Lilly And Company | Kaplanm�� par�ac�k form�lasyonu. |
| US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| US20100016378A1 (en) * | 2005-04-28 | 2010-01-21 | Toshio Suzuki | Method of preventing dihydropyridine compound from degradation |
| TR200504775A1 (tr) | 2005-11-30 | 2007-10-22 | Esen Beki̇r | Kendinden metal takviyeli pvc pencere ve kapı profilleri |
| EP1808164B2 (en) * | 2006-01-05 | 2018-07-04 | Teva Pharmaceutical Industries Ltd | Wet granulation method for preparing pharmaceutical compositions of aripiprazole |
| CA2669266C (en) * | 2006-11-08 | 2014-04-29 | Bristol-Myers Squibb Company | Pyridinone compounds |
| US20080260837A1 (en) * | 2007-04-20 | 2008-10-23 | Qpharma, L.L.C. | Physically stable aqueous suspensions of active pharmaceuticals |
| US8263652B2 (en) * | 2007-10-31 | 2012-09-11 | Sk Biopharmaceuticals Co., Ltd. | Stabilized pediatric suspension of carisbamate |
| WO2009094427A1 (en) | 2008-01-23 | 2009-07-30 | Bristol-Myers Squibb Company | 4-pyridinone compounds and their use for cancer |
-
2011
- 2011-04-29 WO PCT/US2011/034417 patent/WO2011137274A1/en not_active Ceased
- 2011-04-29 JP JP2013508267A patent/JP5820874B2/ja active Active
- 2011-04-29 PL PL11717917T patent/PL2563763T3/pl unknown
- 2011-04-29 SG SG2012076865A patent/SG184891A1/en unknown
- 2011-04-29 MY MYPI2012004708A patent/MY183769A/en unknown
- 2011-04-29 CN CN201180032341.1A patent/CN102971296B/zh active Active
- 2011-04-29 SI SI201130405T patent/SI2563763T1/sl unknown
- 2011-04-29 US US13/643,561 patent/US8911785B2/en active Active
- 2011-04-29 PT PT11717917T patent/PT2563763E/pt unknown
- 2011-04-29 RS RS20150055A patent/RS53790B1/sr unknown
- 2011-04-29 ES ES11717917.6T patent/ES2533075T3/es active Active
- 2011-04-29 HR HRP20150105AT patent/HRP20150105T1/hr unknown
- 2011-04-29 PH PH1/2012/502019A patent/PH12012502019A1/en unknown
- 2011-04-29 EP EP11717917.6A patent/EP2563763B1/en active Active
- 2011-04-29 KR KR1020127031220A patent/KR101897302B1/ko active Active
- 2011-04-29 DK DK11717917.6T patent/DK2563763T3/en active
-
2014
- 2014-09-15 US US14/486,139 patent/US9233948B2/en active Active
-
2015
- 2015-03-18 SM SM201500069T patent/SMT201500069B/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015145426A5 (enExample) | ||
| JP2011037901A5 (enExample) | ||
| HRP20161074T1 (hr) | Benzoksazolski inhibitori kinaza i postupci njihove upotrebe | |
| JP2017527578A5 (enExample) | ||
| JP2013525455A5 (enExample) | ||
| JP2012510458A5 (enExample) | ||
| CN109715626A (zh) | 作为fgfr抑制剂的杂环化合物 | |
| JP2013507415A5 (enExample) | ||
| JP2009506014A5 (enExample) | ||
| JP2011126896A5 (enExample) | ||
| NO20064588L (no) | Delta d-krystallinsk form av ivabradin-hydroklorid, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende den | |
| JP2015524472A5 (enExample) | ||
| MY156552A (en) | Isoxazole derivatives and their use as metabotropic glutamate receptor potentiators | |
| JP2010502730A5 (enExample) | ||
| JP2013523784A5 (enExample) | ||
| NO20060948L (no) | Á-krystallinsk form av ivabradin-hydroklorid, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den | |
| JP2015510916A5 (enExample) | ||
| EP2397476A3 (en) | Indole derivative having PGD2 receptor antagonist activity | |
| NO20060947L (no) | β d-krystalinsk form av ivabradin-hydroklorid, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den | |
| NO20060949L (no) | yd-krystallinsk form avivabradin-hydroklorid, fremgangsmate for dens frem5l1lling 0g farmasoytiske sammensetninger inneholdende den | |
| JP2012507535A5 (enExample) | ||
| NO20063518L (no) | Ny krystallinsk form IV av agomelatin, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den | |
| FI3030557T3 (fi) | Uusia ftalatsinonijohdannaisia ja niiden valmistusmenetelmä | |
| JP2018521121A5 (enExample) | ||
| JP2016508135A5 (enExample) |